Table 2. Antimicrobial susceptibility profiles including minimum inhibitory concentrations from Vitek2 AST-N224.
AST-P600 (bioMérieux, Inc.) and zone diameter from disk diffusion tests after 16 hours incubation on Mueller-Hinton agar of the novel Cupriavidus species.
| Antimicrobial Agent | MICa (μg/mL) | Zone Diameter (mm) | Antimicrobial Agent | MICa (μg/mL) | Zone Diameter (mm) |
|---|---|---|---|---|---|
| Ampicillin /Sulbactam | ≤2 (S)b | Not tested | Aztreonam | ≥64 (R) | Not tested |
| Ticarcillin /Clavulanic Acid | ≤8 (S) | 15 (I, 75/10 μg)b |
Colistin | ≤0.5c (S) | 20 (S, 10 μg) |
| Piperacillin | 64 (I) | 30 (S, 100 μg) |
Gentamicin | ≥16 (R) | 0 (R, 10 μg) |
| Piperacillin /Tazobactam | ≥128 (R) | 40 (S, 100/10 μg) |
Tetracycline | Not tested | 40 (S, 30 μg) |
| Cefotaxime | 2 (S) | Not tested | Ciprofloxacin | 0.5 (S) | 35 (S, 5 μg) |
| Ceftazidime | ≥64 (R) | 15 (I, 30 μg) |
Levofloxacin | Not tested | 35 (S, 5 μg) |
| Cefepime | ≤1 (S) | 35 (S, 30 μg) |
Trimethoprim-/sulfamethoxazole | ≤20 (S) | 40 (S, 1.25/23.75 μg) |
| Ceftriaxone | Not tested | 40 (S, 30 μg) |
Amikacin | 16(S) | Not tested |
| Imipenem | 1 (S) | 30 (S, 10 μg) |
Minocycline | 2 (S) | Not tested |
| Meropenem | ≥16 (R) | 0 (R, 10 μg) |
Tigecycline | ≤0.5 (S) | Not tested |
| Linezolid | ≥8d | Not tested |
Abbreviation: MIC, minimum inhibitory concentration
a Determined by Vitek2 AST-N224 or AST-P600 (for linezolid only) (bioMérieux, Inc.).
b Interpreted according to the breakpoints listed in “Performance Standards for Antimicrobial Disk Susceptibility Tests. 13th Ed. CLSI standard M100” for Acinetobacter spp.
c An identical result was also obtained from broth microdilution test (BMD) which was performed according to the CLSI-EUCAST Polymyxin Breakpoints Working Group
d Susceptibility was not determined due to the lack of breakpoint data for Gram-negative rods.